They will not be releasing results in the abstract

They will not be releasing results in the abstract and poster. So it is unlikely to be "explosive" in respect to stunning results.

Now, whatever they share in March...all depends it can be explosive or a nonevent -optionking

However it is not a nonevent either.

They will present the outline of the Phase I trial to the research community at their key event for the first time. This is very important. They will no doubt cover the primary and secondary outcome measures and trial design, and can share at such information such as "Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT . Enrollment to cohort 3 began in January 2011.”"

This could spur additional interest in the community for further research studies, draw more attention to the Phase I trial and Kevetrin, and lead to some interesting questions and discussions which are not restricted like the abstract and poster session.

(We should also keep in mind that by May 31 the trial will be further along and that will have been announced independent of ASCO)

This could indeed have and "explosive" effect in terms of additional interest from the research community. Although with trials and preclinical research already underway at 3 of the top cancer centers worldwide, and a fourth interested, it is fair to say the interest in Kevetrin is already explosive.

Here are all the details from ASCO about the Trials in Progress parameters. We should keep in mind that the abstract and poster will have been already submitted and current as of now, but they can submit amendments if things change.

http://chicago2013.asco.org/trials-progress